Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401808 | 0.86 | LMNA (0.33) | NT5E | |
| SCHEMBL6396987 | 0.84 | MAPT (0.33) | MAPTNT5EP2RY6P2RY14 | |
| SCHEMBL6398974 | 0.83 | P2RY2 (0.37) | MAPTNT5EP2RY6P2RY14 | |
| SCHEMBL6398232 | 0.80 | DUT (0.35) | P2RY14 | |
| SCHEMBL6403546 | 0.74 | LMNA (0.45) | MAPTNT5EP2RY6P2RY14 | |
| SCHEMBL6403550 | 0.74 | LMNA (0.45) | MAPTNT5EP2RY6P2RY14 | |
| SCHEMBL6401433 | 0.65 | TYMP (0.46) | NT5EP2RY6P2RY14 | |
| SCHEMBL10594890 | 0.63 | P2RY2 (0.54) | NT5EP2RY6P2RY14 | |
| SCHEMBL26472122 | 0.62 | MAPT (0.39) | MAPTNT5EP2RY6P2RY14 | |
| SCHEMBL26012350 | 0.62 | MAPT (0.39) | MAPTNT5EP2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | MAPT 2375/4885NT5E 48/4885P2RY6 712/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | MAPT 2042/4885NT5E 52/4885P2RY6 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.